# Exelixis, Inc. – Consensus ‘buy’ rating and 9.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/exelixis-inc-consensus-buy-rating-and-9-0-upside-potential/4121185400
- Published: 2025-01-31T12:03:05+00:00
- Author: Charlotte Edwards

**Exelixis, Inc.** with ticker code (EXEL) now have 22 confirmed analysts covering
the stock with the consensus suggesting a rating of ‘buy’. The range between the
high target price and low target price is between $43.00 and $23.00 and has a mean
target at $35.93. Given that the stocks previous close was at $32.96 and the analysts
are correct then there would likely be a percentage uptick in value of 9.0%. There
is a 50 day moving average of $34.75 while the 200 day moving average is $27.37.
The company has a market cap of 9.40B. Currently the stock stands at: $32.93 USD

 The potential market cap would be $10,250,216,468 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 21.25, revenue per share of $7.03
and a 12.81% return on assets.

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines
and combination regimens at the forefront of cancer care. It has four products, 
including its flagship molecule, cabozantinib, which is an inhibitor of multiple
tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved
as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and
in combination with Bristol-Myers Squibb Company’s (BMS) OPDIVO (nivolumab), for
hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated
thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic
medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor
of MEK approved as part of multiple combination regimens to treat specific forms
of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the
mineralocorticoid receptor (MR) approved the treatment of hypertension.

Share on:
